DOI:
10.1055/s-00000005
Aktuelle Rheumatologie
LinksClose Window
References
Machado P, Miller A, herbelin L et al.
LB002 safety and tolerability of arimoclomol in patients with sporadic inclusion body myositis: a randomised, double-blind, placebo-contolled, phase IIa proof-of-concept trial.
Ann Rheum Dis 2013;
72: 164
We do not assume any responsibility for the contents of the web pages of other providers.